Back to Search Start Over

The application of fluorescein sodium for the resection of medulloblastoma

Authors :
Zheng-he Chen
Xiang-heng Zhang
Fu-hua Lin
Chang Li
Jie-tian Jin
Zhi-huan Zhou
Si-han Zhu
Zhu-qing Cheng
Sheng Zhong
Zhen-qiang He
Hao Duan
Xia Wen
Jian Wang
Yong-gao Mou
Source :
Journal of Neuro-Oncology. 158:463-470
Publication Year :
2022
Publisher :
Springer Science and Business Media LLC, 2022.

Abstract

Introduction Surgical resection of medulloblastoma (MB) remains a challenge. At present, a variety of tracers have been used for intraoperative tumor visualization. However, there are few reports on the intraoperative visualization of MB. Hence, we reported our experience of applying fluorescein sodium (FS) in MB surgery. Methods We retrospectively analyzed the clinical information of patients with MB confirmed by surgery and pathology from January 2016 to December 2020 from Sun Yat-sen University Cancer Center. A total of 62 patients were enrolled, of which 27 received intraoperative FS and 35 did not. The intraoperative dose of FS was 3 mg/kg. Results Among the 62 patients, 42 were males, and twenty were females. The age of onset in the FS group was 9.588 ± 7.322, which in the non-fluorescein sodium group was 13.469 ± 10.968, p = 0.198. We did not find significant differences in tumor location, tumor size, tumor resection, tumor histology, and preoperative symptoms (hydrocephalus, headache, vomit, balance disorder) between the groups. There was no significant difference in the postoperative symptoms (hydrocephalus, headache, vomiting, balance disorder, and cerebellar mutism). However, patients in the FS group had a relatively low incidence of balance disorder and cerebellar mutism. There was definite fluorescence of tumor in all cases of the FS group, and even the tiny metastatic lesion was visible. No case had side effects related to the use of FS. Conclusions FS is safe and effective in MB surgery. Whether the application of FS for surgery can reduce complications remains to be studied in the future.

Details

ISSN :
15737373 and 0167594X
Volume :
158
Database :
OpenAIRE
Journal :
Journal of Neuro-Oncology
Accession number :
edsair.doi.dedup.....5ba3a65e825775065a7426ff9625531a
Full Text :
https://doi.org/10.1007/s11060-022-04035-2